← Human Trials & Peer-Reviewed Studies

Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans

Plain-language guide to PMID 18843793 (2008): randomized controlled trial study of IGF-1 LR3 in 3 volunteers.

Key Facts

PMID
18843793
Journal
Aging cell
Year
2008
Study type
Randomized Controlled Trial
Authors
Fontana L et al. (5 authors)
DOI
10.1111/j.1474-9726.2008.00417.x

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.

However, the long-term effects of CR with adequate nutrition on circulating IGF-1 levels in humans are unknown.

Here the researchers report data from two long-term CR studies (1 and 6 years) showing that severe CR without malnutrition did not change IGF-1 and IGF-1 : IGFBP-3 ratio levels in humans.

Who Took Part

The study group was 3 volunteers.

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

A time span of 3 weeks appears in the methods.

What Was Measured

However, the long-term effects of CR with adequate nutrition on circulating IGF-1 levels in humans are unknown.

Here the researchers report data from two long-term CR studies (1 and 6 years) showing that severe CR without malnutrition did not change IGF-1 and IGF-1 : IGFBP-3 ratio levels in humans.

Topics PubMed links to this paper include Aging, Caloric Restriction, Dietary Proteins, Energy Intake, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor Binding Proteins and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 in 3 volunteers over 3 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2008 (Aging cell), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.

Our Notes on the Compound

IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.